User: **A 35-year-old man presents to the emergency department with progressive breathlessness over two days. He reports several weeks of fatigue before the dyspnea began. He also notes decreased urination over the past 48 hours. He denies fever, cough, chest pain, hemoptysis, joint pain, rash, or visual disturbance.
His wife adds that over the past six months he has had episodic bilateral swelling of the fingers, ankles, and face — painless, without colour change.
Four years ago, he was evaluated for back pain, suprapubic pain, fatigue, and fever (38.6°C). Urinalysis at that time showed hematuria and proteinuria (3+ blood, 3+ albumin). Urine culture grew mixed flora. Ceftriaxone was prescribed. He was told to follow up but did not.
Six years ago, a rapid plasma reagin (RPR) test was positive at a titre of 1:8, but confirmatory treponemal antibody testing was negative. HIV testing and a Mantoux tuberculin skin test were negative.
He was born in Central America, immigrated six years ago, is married with no children, and is physically active in his job. He takes no medications, does not smoke, drink alcohol, or use drugs.
On presentation to the urgent care clinic earlier that day: Temperature 37.1°C, BP 152/79 mm Hg, HR 102/min, RR 36/min, SpO2 91% on room air. Pale conjunctivae. Chest auscultation: no rales, no wheezing. He was started on 15 L/min oxygen by face mask. SpO2 rose to 95%, dropped to 81% when oxygen reduced to 6 L/min, and rose to 100% at 15 L/min. He was transferred to the ED by ambulance.**
Hello, Chief Resident here.
Key findings include progressive dyspnea with severe hypoxia (refractory to low-flow O2), oliguria, and a history of episodic painless edema. Notably, he has a 4-year history of untreated nephritic-range proteinuria/hematuria and a false-positive RPR, which is a classic marker for antiphospholipid antibodies or systemic autoimmune disease. The absence of rales despite severe hypoxia suggests a pulmonary vascular or alveolar process rather than simple heart failure.
Differential Diagnoses:
Prioritized Tests:
1. Urinalysis with microscopy and UPCR: To confirm active sediment/nephrotic-range protein.
2. Serology Panel: ANA, anti-dsDNA, ANCA, anti-GBM, and C3/C4 levels.
3. Chest CT (Non-contrast): To evaluate for ground-glass opacities suggestive of DAH.
4. Serum Creatinine and Electrolytes: To assess the degree of acute kidney injury.
5. Echocardiogram: To rule out heart failure or pulmonary hypertension.
Hello Attending Consultant here.
Top 3 Differential Diagnoses:
1. SLE with class IV lupus nephritis and DAH (lupus pneumonitis).
2. ANCA-associated vasculitis (MPA) with pulmonary-renal syndrome.
3. Anti-GBM disease (Goodpasture syndrome).
Critique & 6 Specific Improvements to Resident Plan:
- Prioritize immediate bronchoscopy with BAL (not just CT) to confirm DAH and quantify hemorrhage.
- Add urgent anti-dsDNA, complement levels, lupus anticoagulant, and anti-cardiolipin Abs given false-positive RPR.
- Initiate high-dose IV methylprednisolone (1 g/day × 3) empirically while awaiting serologies if DAH suspected.
- Perform urgent renal biopsy within 24 h if stable; avoid if active bleeding.
- Quantify proteinuria with spot UPCR and examine urine sediment for dysmorphic RBCs/casts immediately.
- Order echo with bubble study to exclude intracardiac shunt or pulmonary hypertension.
Avoid over-reliance on non-contrast CT; proceed to serologies and immunosuppression faster. (148 words)
Hello, Expert Clinician here.
Best unifying diagnosis: pulmonary–renal syndrome, most likely SLE with lupus nephritis plus diffuse alveolar hemorrhage (DAH).
Why it fits: weeks of fatigue, prior untreated hematuria/proteinuria, current oliguria/likely AKI, episodic painless edema, severe hypoxemia without wheeze/rales, and a biologic false-positive RPR strongly suggesting antiphospholipid antibodies/SLE. DAH can present with dyspnea/hypoxia even without hemoptysis.
Top differentials:
1. ANCA-associated vasculitis (MPA/GPA): fits pulmonary-renal syndrome; less supportive are absent ENT/systemic vasculitic features and false-positive RPR.
2. Anti-GBM disease: fits DAH + glomerulonephritis; less explanatory for chronic edema and false-positive RPR.
3. Nephrotic/nephritic renal disease with volume overload: edema/oliguria fit, but marked hypoxemia with clear lungs is less convincing.
Key pivot: the combination of glomerular renal disease + severe unexplained hypoxemia + false-positive RPR points away from infection and toward autoimmune pulmonary-renal disease, especially lupus.
Most important next move: treat as presumed DAH/pulmonary-renal syndrome now: ICU, high-dose IV methylprednisolone immediately, urgent CBC/Cr/UA with microscopy, C3/C4, ANA/dsDNA, ANCA, anti-GBM, antiphospholipid antibodies, chest imaging/bronchoscopy if stable, and nephrology for urgent renal biopsy.
Teaching pearl: DAH often occurs without hemoptysis; falling hemoglobin and new infiltrates may be the clue.
User: **On arrival at the ED: Temperature 36.9°C, BP 173/89 mm Hg, HR 95/min, RR 36/min, SpO2 88% on room air, 100% on high-flow oxygen via non-rebreather mask. Pale skin and conjunctivae with slight brownish injection of conjunctivae. Skin: Hypopigmented macules on the right temple and both lower cheeks; hyperpigmented macules on the bridge of the nose. Chest: Bibasilar rales now present. Remainder of examination: normal.
Initial investigations: Hb 4.5 g/dL (13.5-17.5). WBC 11,500. Platelets 236,000. BUN 158 mg/dL. Creatinine 30.65 mg/dL. eGFR 2 mL/min. Sodium 139 mmol/L. Potassium 4.8 mmol/L. Bicarbonate 6.6 mmol/L (23.0-31.9). Anion gap 32. Calcium 3.6 mg/dL. Ionized calcium 0.55 mmol/L (1.14-1.30). Phosphorus 16.5 mg/dL. CK 3,169 U/L. Troponin T 0.12 ng/mL (<0.03). PT 15.3 sec (11.0-13.7). aPTT 35.2 sec (21.0-33.0). d-Dimer 6,908 ng/mL (<500). Fibrinogen 764 mg/dL. Haptoglobin 6.0 mg/dL (16-199).
Urinalysis: 3+ blood, 3+ albumin, RBCs 20-50/HPF, WBCs 10-20/HPF, hyaline casts 10-20/LPF, granular casts 0-2/LPF, muddy brown casts few.
Chest X-ray: Bilateral central and perihilar air-space opacities, confluent in the right lower lobe. Slight cardiomegaly. No pleural effusions.
ECG: Sinus tachycardia. Nonspecific ST-T wave changes.
Cardiac ultrasound: Normal global cardiac function, normal right ventricular size, no pericardial effusion. Findings consistent with pulmonary edema.
Serum iron 29 mcg/dL. Iron-binding capacity 197 mcg/dL. Ferritin 258 ng/mL.**
Hello, Chief Resident here.
Updated Key Findings:
The patient is in profound multi-organ failure: severe normocytic anemia (Hb 4.5), Stage 3 AKI (Cr 30.65) with uremic metabolic acidosis (Bicarb 6.6), and hyperphosphatemia-induced hypocalcemia. The "muddy brown casts" suggest Acute Tubular Necrosis (ATN), likely complicating a primary glomerulonephritis. The malar-pattern skin changes and bibasilar rales, combined with CXR opacities and a high D-dimer, reinforce a pulmonary-renal syndrome.
Differential Diagnoses:
Prioritized Tests/Interventions:
1. Emergent Hemodialysis: For life-threatening uremia, acidosis, and volume management.
2. Pulse-dose Methylprednisolone (1g IV): Immediate immunosuppression.
3. Serology: ANA, anti-dsDNA, C3/C4, ANCA, anti-GBM.
4. Peripheral Blood Smear: To evaluate for schistocytes (TMA).
5. Urgent Renal Biopsy: Once stabilized by dialysis to confirm the underlying pathology.
Hello Attending Consultant here.
Top 3 Differential Diagnoses:
1. SLE with class IV lupus nephritis, DAH, and TMA (lupus-associated APS).
2. ANCA-associated vasculitis (MPA) with pulmonary-renal syndrome and secondary ATN.
3. Anti-GBM disease with superimposed ATN/hemorrhage.
Critique & 6 Specific Improvements to Resident Plan:
- Add immediate plasmapheresis to pulse steroids for suspected DAH/TMA.
- Order urgent peripheral smear, LDH, ADAMTS13 to rule out TMA/MAHA.
- Prioritize bronchoscopy with BAL over biopsy if unstable; quantify serial Hb.
- Include lupus anticoagulant, anti-cardiolipin, anti-β2GP1 given false-positive RPR.
- Initiate CRRT rather than intermittent HD for hemodynamic instability and hyperphosphatemia.
- Perform non-contrast chest CT immediately to differentiate DAH from edema.
- Avoid empiric biopsy until coagulopathy corrected and bleeding stabilized.
(137 words)
Hello, Expert Clinician here.
Best unifying diagnosis: autoimmune pulmonary–renal syndrome, still most likely SLE, specifically advanced lupus nephritis/rapidly progressive GN with pulmonary edema or DAH, now with uremic crisis and possible secondary TMA/hemolysis.
Why it fits: prior years of glomerular hematuria/proteinuria, episodic edema, biologic false-positive RPR, possible malar/discoid pigment changes, profound renal failure, severe anemia, and bilateral air-space opacities with normal cardiac function. UA is glomerular, though few muddy brown casts suggest superimposed ATN, not a primary ATN process.
Top differentials:
1. ANCA vasculitis: strong pulmonary-renal alternative; less supported by skin/RPR clues.
2. Anti-GBM disease: fits DAH + RPGN; less explanatory for chronicity/false-positive RPR.
3. TMA/APS/aHUS: low haptoglobin and severe renal failure fit, but platelets are normal and pulmonary findings are less classic.
Key pivot: this is no longer just diagnostic uncertainty—he has life-threatening indications for renal replacement therapy now (pH-threatening acidosis, uremia, severe electrolyte-mineral derangement, pulmonary edema).
Most important next move: ICU, emergent dialysis, transfuse packed RBCs, and start pulse IV methylprednisolone while sending ANA/dsDNA/C3/C4/ANCA/anti-GBM/APLS labs; biopsy later if stabilized.
Teaching pearl: In pulmonary-renal syndromes, pulmonary edema and DAH can coexist, especially in severe renal failure.
User: **The patient was intubated for worsening tachypnea and fatigue. Mechanical ventilation begun. A radial arterial catheter, internal jugular triple-lumen catheter, and hemodialysis catheter were placed. Haemodialysis initiated. Eight units of leukocyte-reduced red cells transfused over 23 hours. Methylprednisolone 1 g IV daily for 3 days started empirically.
Bronchoscopy: Thick, red mucus in mainstem and right lower lobe bronchi. Bronchoalveolar lavage with serial aliquots showed increasingly red return — 300 RBCs/mm3 in first tube, 24,500 RBCs/mm3 in fourth tube. WBCs: 975/mm3 first tube, 1,475/mm3 fourth tube, with 84% neutrophils in fourth tube. Gram stain: leukocytes without organisms. Fungal, AFB, viral studies: negative.
CT chest (PE protocol): Bilateral perihilar ground-glass opacities (R > L). Mild interlobular septal thickening. Small right pleural effusion. No pulmonary emboli.
Additional labs: C3 59 mg/dL (86-184). C4 10 mg/dL (16-38). Anti-cardiolipin IgG 101.2 GPL (0-15). Anti-cardiolipin IgM 14.0 MPL (0-15). ANA 1:1280 homogeneous. Anti-dsDNA 1:80. Anti-GBM antibody: Negative. ANCA (PR3, MPO): Negative. Anti-histone antibody: Negative. Rheumatoid factor: Negative. Serum protein electrophoresis: Diffuse IgG increase.
Dramatic improvement after steroids — extubated within 48 hours. Transferred out of ICU on third day.**
Hello, Chief Resident here.
Updated Key Findings:
The diagnosis is now confirmed as a pulmonary-renal syndrome due to Systemic Lupus Erythematosus (SLE). Key evidence includes the high-titer ANA (1:1280), anti-dsDNA, and hypocomplementemia (C3/C4). The bronchoscopy (increasingly bloody aliquots) definitively confirms Diffuse Alveolar Hemorrhage (DAH). Furthermore, the high anti-cardiolipin IgG explains the prior false-positive RPR and suggests Antiphospholipid Syndrome (APS), which likely contributed to the renal failure via thrombotic microangiopathy.
Differential Diagnoses:
Prioritized Tests/Management:
1. Urgent Renal Biopsy: To determine the class of lupus nephritis and the extent of chronicity vs. active inflammation/TMA.
2. Continue Pulse Steroids: Transition to oral prednisone taper after 3 days of IV methylprednisolone.
3. Induction Therapy: Discuss Mycophenolate Mofetil or Cyclophosphamide (Euro-Lupus protocol) given the severity.
4. Anticoagulation Evaluation: Assess the need for anticoagulation given high-titer APS antibodies, balanced against DAH risk.
5. Repeat Hemoglobin and Coagulation Profile: Monitor for stabilization after transfusion and dialysis.
Hello Attending Consultant here.
Top 3 Differential Diagnoses:
1. SLE with class IV lupus nephritis, DAH, and secondary APS-associated TMA.
2. Lupus nephritis with DAH plus superimposed ATN from uremic crisis.
3. Catastrophic APS with pulmonary-renal involvement (lupus overlap).
Critique & 6 Specific Improvements:
- Initiate cyclophosphamide or MMF induction immediately post-biopsy; steroids alone insufficient for class IV.
- Add hydroxychloroquine 400 mg daily for long-term SLE/APS management.
- Start therapeutic anticoagulation (heparin bridge to warfarin) now that DAH resolved, given high-titer aCL.
- Perform urgent renal biopsy within 48 h to guide immunosuppression intensity and prognosis.
- Monitor serial complements, dsDNA, and Hb to gauge treatment response.
- Screen for other APS manifestations (echo for Libman-Sacks, brain MRI if indicated).
- Transition to CRRT weaning and outpatient nephrology-rheumatology co-management.
(138 words)
Hello, Expert Clinician here.
Best unifying diagnosis: SLE presenting as pulmonary–renal syndrome: diffuse alveolar hemorrhage (DAH) plus severe lupus nephritis causing dialysis-dependent renal failure; antiphospholipid antibody positivity likely explains the prior false-positive RPR and may signal APS overlap.
Why it fits: BAL with progressively bloodier aliquots confirms DAH; ANA 1:1280, anti-dsDNA positive, low C3/C4, and marked anticardiolipin IgG strongly support lupus. Anti-GBM and ANCA are negative. Rapid steroid response is also supportive.
Top differentials:
1. Catastrophic/renal APS overlap: possible given high anticardiolipin, but platelets are normal and DAH from APS alone is less typical.
2. ANCA vasculitis / anti-GBM: now much less likely with negative serologies and strongly lupus-consistent immune profile.
3. Pure volume-overload pulmonary edema: insufficient because bronchoscopy proved hemorrhage.
Key pivot: the case turned when bronchoscopy confirmed DAH and serologies showed immune-complex lupus rather than pauci-immune or anti-GBM disease.
Most important next move: urgent kidney biopsy to classify lupus nephritis and assess TMA/chronicity, then start definitive induction therapy (typically cyclophosphamide or MMF with steroids; continue dialysis support).
Teaching pearl: False-positive nontreponemal syphilis tests are a classic clue to antiphospholipid antibodies/SLE.
User: **On hospital day 5, a renal biopsy was performed.
Light microscopy: Proliferative-appearing glomeruli with cellular and fibrocellular crescents. GBM markedly thickened with "wire loop" appearance on H&E. PAS stain: GBM duplication ("tram-track"). Many globally sclerosed glomeruli indicating chronicity. Advanced tubular atrophy and interstitial fibrosis with mononuclear infiltrate. Small vessels: occlusive fibrin thrombi in arterioles with intramural fragmented RBCs (schistocytes) and mucoid intimal change — diagnostic of thrombotic microangiopathy.
Immunofluorescence: Strong granular staining for IgG, IgM, IgA, C3, C1q, kappa, and lambda light chains — "full house" pattern. Granular deposits along GBM, mesangium, and tubular basement membrane. Fibrin staining in thrombosed vessels.
Electron microscopy: Massive subendothelial, mesangial, and intramembranous electron-dense immune-complex deposits. Rare subepithelial deposits. Deposits show concentric curvilinear "fingerprint" substructure. Tubuloreticular inclusions in endothelial-cell cytoplasm.**
Hello, Chief Resident here.
Updated Key Findings:
The renal biopsy provides the definitive diagnosis: Class IV Lupus Nephritis (Diffuse Proliferative) with a "full house" immunofluorescence pattern and pathognomonic "fingerprint" deposits on EM. Critically, the biopsy also reveals Thrombotic Microangiopathy (TMA) with fibrin thrombi and mucoid intimal change, explaining the extreme renal failure (Cr 30) and low haptoglobin. The presence of tubuloreticular inclusions is a classic ultrastructural marker of interferon-alpha activity in SLE.
Differential Diagnoses:
Management Recommendations:
1. Induction Therapy: Initiate Cyclophosphamide (NIH or Euro-Lupus) or Mycophenolate Mofetil plus continued steroids.
2. Anticoagulation: Start therapeutic anticoagulation (e.g., Heparin) for TMA/APS, now that DAH has stabilized.
3. Hydroxychloroquine: Essential for all SLE patients to reduce flares and thrombotic risk.
4. Long-term Dialysis Planning: Given the "globally sclerosed glomeruli" and "advanced tubular atrophy," the prognosis for renal recovery is guarded; evaluate for permanent access.
5. Plasma Exchange: Consider if TMA/DAH features persist despite steroids.
Hello Attending Consultant here.
Top 3 Differential Diagnoses:
1. SLE class IV lupus nephritis with DAH and APS-associated TMA.
2. Lupus nephritis with TMA plus superimposed ATN.
3. Catastrophic APS (SLE overlap) with pulmonary-renal TMA.
Critique & 6 Specific Improvements:
- Classify as ISN/RPS class IV-G with TMA and chronicity index >50%; guide prognosis.
- Add rituximab if refractory to cyclophosphamide/MMF given TMA component.
- Initiate lifelong anticoagulation (warfarin target INR 2-3 or DOAC) post-DAH resolution.
- Continue hydroxychloroquine 400 mg daily and monitor for osteonecrosis.
- Perform repeat serologies (C3/C4, dsDNA, aCL) at 4-6 weeks to assess response.
- Plan multidisciplinary lupus clinic follow-up with nephrology/rheumatology.
- Avoid further biopsy unless new flare; focus on infection prophylaxis.
(142 words)
Hello, Expert Clinician here.
Best unifying diagnosis: Severe SLE with diffuse proliferative lupus nephritis (ISN/RPS class IV, likely IV-G) causing pulmonary–renal syndrome, plus renal thrombotic microangiopathy, likely APS-associated overlap.
Why it fits: biopsy is decisive—wire loops, crescents, full-house IF, massive subendothelial immune-complex deposits, fingerprint deposits, and tubuloreticular inclusions are classic lupus nephritis. Arteriolar fibrin thrombi with fragmented RBCs confirm TMA. This integrates prior false-positive RPR/anticardiolipin positivity, DAH, hypocomplementemia, and dsDNA positivity.
Top differentials:
1. Catastrophic APS overlap: fits TMA and aCL positivity, but immune-complex nephritis is dominant, not isolated APS nephropathy.
2. ANCA vasculitis / anti-GBM: now essentially excluded by biopsy/serologies.
3. Primary TMA (TTP/aHUS): vascular lesions fit, but biopsy and lupus serologies clearly point to secondary TMA.
Key pivot: the biopsy converted “suspected lupus” into proven class IV lupus nephritis with TMA and substantial chronicity, which strongly impacts prognosis.
Most important next move: start definitive induction therapy now (high-dose steroids plus cyclophosphamide or MMF), add hydroxychloroquine, and reassess when/if safe to anticoagulate for APS/TMA given recent DAH.
Teaching pearl: In lupus, “full-house” IF + wire-loop lesions + tubuloreticular inclusions is a powerful diagnostic triad.
User: **Anti-GBM was negative. ANCA (anti-PR3, anti-MPO) were negative. ANA 1:1280. Anti-dsDNA 1:80. The patient received prednisone 60 mg daily. Cyclophosphamide was planned — 500 mg IV every 2 weeks for 3 months. He received the first dose while in hospital.
Platelet count fell to a nadir of 90,000 during admission. Because of positive lupus anticoagulant and anti-cardiolipin antibodies, with thrombotic microangiopathy on biopsy, anticoagulation with low-molecular-weight heparin was started, transitioning to warfarin.
The patient was discharged on day 11 with outpatient haemodialysis. He initially had poor follow-up but continued dialysis and oral cyclophosphamide. His renal function gradually improved — urine output resumed after several months, creatinine declined, and dialysis was reduced to twice-weekly sessions. Fifteen months after discharge, dialysis and prednisone were discontinued. Seven months after stopping dialysis: BUN 29 mg/dL, creatinine 3.26 mg/dL.
What is the final diagnosis? How was it established? What are the key teaching points from this case?**
Hello, Chief Resident here.
Final Diagnosis:
Systemic Lupus Erythematosus (SLE) presenting as Pulmonary-Renal Syndrome, specifically Class IV Lupus Nephritis (Diffuse Proliferative) with Diffuse Alveolar Hemorrhage (DAH) and Secondary Antiphospholipid Syndrome (APS) causing Renal Thrombotic Microangiopathy (TMA).
How it was established:
1. Clinical/Serological: Met ACR/SLICC criteria for SLE (malar-like rash, high-titer ANA, anti-dsDNA, hypocomplementemia, and renal/hematologic involvement).
2. Pulmonary: Bronchoscopy with serial BAL aliquots confirmed DAH (increasingly bloody return).
3. Renal Biopsy: Gold standard confirmation showing "full-house" IF, "wire-loop" lesions, and "fingerprint" deposits (Class IV LN). Arteriolar fibrin thrombi and schistocytes confirmed TMA.
4. APS: Established by biologic false-positive RPR and high-titer anti-cardiolipin IgG/lupus anticoagulant.
Key Teaching Points:
1. DAH Presentation: Hemoptysis is absent in up to 33% of DAH cases; unexplained hypoxia and falling hemoglobin are critical clues.
2. Biologic False-Positive RPR: A classic "red flag" for APS/SLE that should prompt immediate serologic screening.
3. TMA in Lupus: The presence of TMA on renal biopsy signifies a poorer prognosis and necessitates consideration of anticoagulation once bleeding (DAH) is controlled.
4. Renal Recovery: Even with a creatinine of 30 mg/dL and dialysis dependence, aggressive induction (cyclophosphamide/steroids) can lead to significant renal recovery in SLE.
Hello Attending Consultant here.
Top 3 Differential Diagnoses:
1. SLE class IV-G lupus nephritis with DAH and APS-associated renal TMA.
2. Catastrophic APS (SLE overlap) with pulmonary-renal TMA.
3. Lupus nephritis with secondary TMA plus uremic ATN.
Critique & 6 Specific Improvements:
- Classify biopsy as ISN/RPS IV-G (A/C) with TMA, activity/chronicity indices, and tubuloreticular inclusions.
- Add rituximab for refractory TMA or persistent dsDNA elevation post-cyclophosphamide.
- Initiate lifelong anticoagulation (warfarin INR 2-3) after DAH resolution given lupus anticoagulant and biopsy TMA.
- Continue hydroxychloroquine 400 mg daily with ophthalmologic screening.
- Monitor serial C3/C4, dsDNA, aCL titers, and Hb at 4-6 weeks to gauge response.
- Plan multidisciplinary lupus-nephrology clinic with infection prophylaxis (PJP, TB).
- Emphasize renal recovery potential despite high chronicity; avoid premature transplant evaluation.
(138 words)
Hello, Expert Clinician here.
Final diagnosis: SLE presenting as pulmonary–renal syndrome: diffuse alveolar hemorrhage (DAH) plus severe diffuse proliferative lupus nephritis (ISN/RPS class IV, likely IV-G A/C) with renal thrombotic microangiopathy, most likely APS-associated overlap.
How it was established:
- DAH confirmed by bronchoscopy/BAL with progressively bloodier aliquots.
- SLE serologies: ANA 1:1280, anti-dsDNA positive, low C3/C4, strong anticardiolipin/lupus anticoagulant.
- Renal biopsy was decisive: crescents, wire-loop lesions, full-house IF, massive subendothelial immune-complex deposits, fingerprint deposits, tubuloreticular inclusions, and arteriolar fibrin thrombi with fragmented RBCs diagnostic of TMA.
- ANCA and anti-GBM negative, arguing against pauci-immune vasculitis/Goodpasture disease.
Key teaching points:
1. DAH may occur without hemoptysis; hypoxemia + severe anemia + diffuse opacities is enough to suspect it.
2. False-positive RPR / positive aPL is a major clue to SLE/APS.
3. In lupus, renal biopsy defines class, chronicity, and TMA, which changes prognosis and treatment.
4. Even dialysis-dependent lupus nephritis can recover renal function with aggressive immunosuppression and supportive care.